PMID- 27932124 OWN - NLM STAT- MEDLINE DCOM- 20170531 LR - 20181202 IS - 1873-2623 (Electronic) IS - 0041-1345 (Linking) VI - 48 IP - 9 DP - 2016 Nov TI - De Novo Donor-Specific Anti-Human Leukocyte Antigen Antibody Detection in Long-Term Adult Liver Transplantation. PG - 2980-2982 LID - S0041-1345(16)30540-1 [pii] LID - 10.1016/j.transproceed.2016.08.037 [doi] AB - INTRODUCTION: Information about the consequences of de novo donor-specific anti-human leukocyte antigen (DSA) antibody development in the long term after adult liver transplantation (LT) is scarce. We conducted a cross-sectional study in LT patients with a follow-up of at least 6 years. METHODS: A total of 28 adult LT patients were included, with a median follow-up of 77 months (range, 63 to 96) and without preformed anti- human leukocyte antigen (HLA) antibodies prior to LT. The anti-HLA identification was performed with LABScreen Single Antigen, whereas the ability to fix the complement was demonstrated with C1q test (One Lambda). In both assays, a value >3.500 mean fluorescence intensity (MFI) was considered positive. The anti-HLA antibody specificities were compared with donor HLA antigens to confirm them as DSA. Hepatic fibrosis was assessed by transient elastography. RESULTS: In 5 patients (17.8%), de novo DSA were detected, all them against DQ locus. In all of these cases (100%) the complement fixation was confirmed by C1q binding. The grade of hepatic fibrosis in de novo DSA patients was significantly higher compared with No-DSA patients (13.2 +/- 9.2 KPa vs 7.3 +/- 3.7 KPa; P = .02). It is noteworthy that in both groups of patients the levels of liver function tests (LFT) at the time of the study were normal or near the normal range with no difference between patients with or without de novo DSA. CONCLUSIONS: Our preliminary results are consistent with those previously demonstrated in pediatric LT, where de novo DSA production and humoral response could contribute to the liver fibrosis observed in the long term after LT in pediatric patients with normal or near-normal LFT. CI - Copyright A(c) 2016 Elsevier Inc. All rights reserved. FAU - San Segundo, D AU - San Segundo D AD - Immunology Unit, University Hospital Marques de Valdecilla, Santander, Spain; Instituto de Investigacion Marques de Valdecilla, Santander, Spain. FAU - Alonso, C AU - Alonso C AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Ruiz, P AU - Ruiz P AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Romon, I AU - Romon I AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Hematology Unit, University Hospital Marques de Valdecilla, Santander, Spain. FAU - Arias-Loste, M T AU - Arias-Loste MT AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Cuadrado, A AU - Cuadrado A AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Puente, A AU - Puente A AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Casafont, F AU - Casafont F AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Lopez-Hoyos, M AU - Lopez-Hoyos M AD - Immunology Unit, University Hospital Marques de Valdecilla, Santander, Spain; Instituto de Investigacion Marques de Valdecilla, Santander, Spain. FAU - Crespo, J AU - Crespo J AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. FAU - Fabrega, E AU - Fabrega E AD - Instituto de Investigacion Marques de Valdecilla, Santander, Spain; Gastroenterology and Hepatology Unit, University Hospital Marques de Valdecilla, Faculty of Medicine, Santander, Spain. Electronic address: digfge@humv.es. LA - eng PT - Journal Article PL - United States TA - Transplant Proc JT - Transplantation proceedings JID - 0243532 RN - 0 (Antibodies, Anti-Idiotypic) RN - 0 (HLA Antigens) RN - 0 (Isoantibodies) SB - IM EIN - Transplant Proc. 2017 Oct;49(8):1963. PMID: 28923656 MH - Adult MH - Antibodies, Anti-Idiotypic/*immunology MH - Cross-Sectional Studies MH - End Stage Liver Disease/immunology/*surgery MH - Female MH - Graft Rejection/immunology MH - Graft Survival/immunology MH - HLA Antigens/*immunology MH - Histocompatibility Testing MH - Humans MH - Isoantibodies/immunology MH - *Liver Transplantation MH - Male MH - Middle Aged MH - Retrospective Studies MH - Sensitivity and Specificity MH - Tissue Donors EDAT- 2016/12/10 06:00 MHDA- 2017/06/01 06:00 CRDT- 2016/12/10 06:00 PHST- 2016/05/20 00:00 [received] PHST- 2016/07/21 00:00 [revised] PHST- 2016/08/04 00:00 [accepted] PHST- 2016/12/10 06:00 [entrez] PHST- 2016/12/10 06:00 [pubmed] PHST- 2017/06/01 06:00 [medline] AID - S0041-1345(16)30540-1 [pii] AID - 10.1016/j.transproceed.2016.08.037 [doi] PST - ppublish SO - Transplant Proc. 2016 Nov;48(9):2980-2982. doi: 10.1016/j.transproceed.2016.08.037.